July 2021—Qiagen and DiaSorin launched the Liaison LymeDetect assay for markets accepting the CE mark, as an aid to detect early Lyme borreliosis infection on the DiaSorin Liaison XL and Liaison XS platforms.
The Liaison LymeDetect combines detection of IgG and IgM antibodies and cellular immunity through a specific interferon-gamma release assay, stimulated by specific Lyme peptides using QuantiFeron LymeDetect technology. In clinical studies the assay showed a sensitivity of 74 percent versus that of existing alternative methods and a diagnostic specificity of 100 percent within 21 days from the first evidence of infection.
Under the development agreement, DiaSorin is responsible for commercialization of the Liaison LymeDetect while Qiagen and DiaSorin are jointly responsible for development and production of the solution.